home / stock / achv / achv news

ACHV News and Press, Achieve Life Sciences Inc. From 11/09/21

Stock Information
Company Name: Achieve Life Sciences Inc.
Stock Symbol: ACHV
Market: NASDAQ
Website: achievelifesciences.com
Menu
ACHV ACHV Quote ACHV Short ACHV News ACHV Articles ACHV Message Board
Get ACHV Alerts

News, Short Squeeze, Breakout and More Instantly...
ACHV - Achieve Life Sciences EPS beats by $0.40

Achieve Life Sciences (NASDAQ:ACHV): Q3 GAAP EPS of -$0.71 beats by $0.40. As of September 30, 2021, Achieve’s cash equivalents, and restricted cash was $33.4 million.  Press Release For further details see: Achieve Life Sciences EPS beats by $0.40

ACHV - Achieve Reports Financial Results for Third Quarter 2021 and Provides Update on Cytisinicline Development

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 09, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, to...

ACHV - Achieve Life Sciences Q3 2021 Earnings Preview

Achieve Life Sciences (NASDAQ:ACHV) is scheduled to announce Q3 earnings results on Tuesday, November 9th, after market close. The consensus EPS Estimate is -$1.16 Over the last 3 months, EPS estimates have seen 2 upward revisions and 2 downward. For further details see: Achieve Life Sc...

ACHV - Achieve Life Sciences Announces Participation in November Investor Conferences

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, t...
ACHV - Achieve Life Sciences Announces FDA Acceptance of IND Application for Cytisinicline's Second Planned Indication for Nicotine E-cigarette Cessation

SEATTLE, Wash and VANCOUVER, British Columbia, Nov. 02, 2021 (GLOBE NEWSWIRE) -- -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, to...

ACHV - Achieve Life Sciences to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 9, 2021

Seattle, WA/ Vancouver, BC , Oct. 26, 2021 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today an...

ACHV - LCID, SDC and ABCL among pre market gainers

Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroesophageal cancer AbCell...
ACHV - Achieve Life Sciences to Participate in Upcoming Investor Conferences

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that...

ACHV - Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference

SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, announced that cytis...

ACHV - Achieve Life Sciences to Participate in Two Upcoming Investor Conferences

SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that Jo...
Previous 10 Next 10